Vulnerability of the endocrine system to xenobiotic influence

Regulatory Toxicology and Pharmacology

Volumn 26, Issue 1 I, 1997, Pages 9-29

  Neubert, Diether ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; ANTIESTROGEN; CLOMIFENE; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ENVIRONMENTAL CHEMICAL; ESTRADIOL; ESTROGEN; ESTRONE; FINASTERIDE; KETOCONAZOLE; PESTICIDE; PROGESTERONE; SEX HORMONE; TAMOXIFEN; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; CONFERENCE PAPER; ENDOCRINE DISEASE; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; MAMMALIA;

EID: 0030818340     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1997.1149     Document Type: Conference Paper

References (104)

1. Andersson, S., and Russell, D. W. (1990). Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc. Natl. Acad. Sci. USA 87, 3640-3644.
2. Aral, Y., and Gorski, R. A. (1968). Critical exposure time for andro-genization of the rat hypothalamus determined by antiandrogen injection. Proc. Soc. Exp. Biol. N.Y. 127, 590.
3. Bancroft, J. (1993). Impact of environment, stress, occupational, and other hazards on sexuality and sexual behavior. Environ. Health Perspect. 101(Suppl.), 101-107.
4. Beato, M. (1989). Gene regulation by steroid hormones. Cell 56, 335- 344.
5. Belchetz, P. E., Plant, T. M., Nakai, Y., Keogh, E. J., and Knobil, E. (1978). Hypophyseal response to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 202, 631-641.
6. Bibbo, M., Gill, W. B., Azizi, F., Blough, R., Fang, V. S., Rosenfield, R. L., Schumacher, G. F. B., Sleeper, K., Sonek, M. G., and Wied, G. L. (1977). Follow-up study of male and female offspring of DES-exposed mothers. Obstet. Gynecol. 49, 1-8.
7. Bjerke, D. L., and Peterson, R. E. (1994). Reproductive toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in male rats: Different effects of in utero versus lactational exposure. Toxicol. Appl. Pharmacol. 127, 241-249.
8. Bjerke, D. L., Sommer, R. J., Moore, R. W., and Peterson, R. E. (1994a). Effects of in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on responsiveness of the male rat reproductive system to testosterone stimulation in adulthood. Toxicol. Appl. Pharmacol. 127, 250-257.
9. Bjerke, D. L., Brown, T. J., MacLusky, N. J., Hochberg, R. B., and Peterson, R. E. (1994b). Partial demasculinization and feminization of sex behavior in male rats by in utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin is not associated with alterations in estrogen receptor binding or volumes of sexually differentiated brain nuclei. Toxicol. Appl. Pharmacol. 127, 258-267.
10. Boys, E. M. (1970). Testicular atrophy from analgesic drugs. J. Clin. Pharmacol. 10, 222.
11. Cenedella, R. J., and Crouthamel, W. G. (1973). Effect of aspirin upon male mouse fertility. Prostaglandins 4, 285-290.
12. Chahoud, I., Hartmann, J., Rune, G. M., and Neubert, D. (1992). Reproductive toxicity and toxicokinetics of 2,3,7,8-terachlorodibenzo-p-dioxin. 3. Effects of single doses on the testis of male rats. Arch. Toxicol. 66, 567-572.
13. Chahoud, I., Krowke, R., Schimmel, A., Merker, H.-J., and Neubert, D. (1989). Reproductive toxicity and toxicokinetics of 2,3,7,8-terachlorodibenzo-p-dioxin. 1. Effects of high doses on the fertility of male rats. Arch. Toxicol. 66, 567-572.
14. Chahoud, I., Stahlmann, R., Bochert, G., Dillmann, I., and Neubert, D. (1988). Gross-structural defects in rats after acyclovir application on day 10 of gestation. Arch. Toxicol. 62, 8-14.
15. Clark, R. L., Anderson, C. A., Prahalada, S., Robertson, R. T., Lochry, E. A., Leonard, Y. M., Stevens, J. L., and Hoberman, A. M. (1993). Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5α-reductase inhibitor. Toxicol. Appl. Pharmacol. 119, 34-40.
16. Clark, R. L., Antonello, J. M., Grossman, S. J., Wise, L. D., Anderson, C., Bagdon, W. J., Prahalada, S., MacDonald, J. S., and Robertson, R. T. (1990). External genitalia abnormalities in male rats exposed in utero to finasteride, a 5α-reductase inhibitor. Teratology 42, 91-100.
17. Clemens, L. G., Gladue, B. A., and Coniglio, L. P. (1978). Prenatal endogenous androgenic influences on masculine sexual behavior and genital morphology in male and female rats. Horm. Behav. 10, 40-53.
18. Collier, J. G., and Flower, R. J. (1971). Effects of aspirin on human seminal prostaglandins. Lancet ii, 852.
19. Cooke, P. S. (1991). Thyroid hormones and testis development: A model system for increasing testis growth and sperm production. Ann. N.Y. Acad. Sci. 637, 122-132.
20. Creasy, D. M., Flynn, J. C., Gray, T. J. B., and Butler, W. H. (1985). A quantitative study of stage-specific spermatocyte damage following administration of ethylene glycol monomethyl ether in the rat. Exp. Mol. Pathol. 43, 321-336.
21. Creasy, G. W., Kafrissen, M. E., and Upmalis, D. (1992). Review of the endometrial effects of estrogens and progestins. Obstet. Gynecol. Surv. 47, 654-678.
22. Dalsenter, P. R., Faqi, A. S., Webb, J., Merker, H.-J., and Chahoud, I. (1997). Reproductive toxicity and toxicokinetics of lindane in the male offspring of rats exposed during lactation. Hum. Exp. Toxicol. 16, 146-153.
23. DeVito, J. M., Thomas, T., Martin, E., Umbreit, H. T., and Gallo, A. M. (1992). Antiestrogenic action of 2,3,7,8-tetrachlorodibenzop-dioxin: Tissues-specific regulation of estrogen receptor in CD1 mice. Toxicol. Appl. Pharmacol. 113, 284-292.
24. DeVito, J. M., Thomas, T., Umbreit, T., and Gallo, M. (1990). Antiestrogenicity of TCDD involves the down regulation of estrogen receptor mRNA and protein. Toxicologist 10, 981.
25. Egeland, G. M., Sweeney, M. H., Fingerhut, M. A., Wille, K. K., Schnorr, T. M., and Halperin, W. E. (1994). Total serum testosterone and gonadotropins in workers exposed to dioxin. Am. J. Epidemiol. 139, 272-281.
26. Ellsworth, K., and Harris, G. (1995). Expression of the type 1 and 2 steroid 5α-reductases in human fetal tissue. Biochem. Biophys. Res. Commun. 215, 774-780.
27. Evans, R. M. (1988). The steroid and thyroid hormone receptor superfamily. Science 240, 889-895.
28. Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., and Parker, M. G. (1990). Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA 87, 6883-6887.
29. Feldman, D. (1986). Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 4, 409-420.
30. Fitzsimmonds, M. P. (1944). Gynecomastia in stilboestrol workers. Br. J. Ind. Med. 1, 235-237.
31. Galand, P., Mairesse, N., Degraef, C., and Rooryck, J. (1987). o,p′-DDT (1,1,1-trichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)-ethane) is a purely estrogenic agonist in the rat uterus in vivo and in vitro. Biochem. Pharmacol. 36, 397-400.
32. Gardner, C. R, Tully, W. R., and Hedgecock, C. R. (1992). The rapidly expanding range of neuronal benzodiazepine receptor ligands. Prog. Neurobiol. 40, 1-61.
33. Gardner, C. R. (1988). Functional in vivo correlates of the benzodiazepine agonist-inverse agonist continuum. Prog. Neurobiol. 31, 425-476.
34. Gorski, R. A., Gordon, J. H., Shryne, J. E., and Southam, A. M. (1978). Evidence for a morphological sex difference within the medial preoptic area of the rat brain. Brain Res. 148, 333-346.
35. Gorski, R. A., Harlan, R. E., Jacobson, C. D., Shryne, J. E., and Southam, A. M. (1980). Evidence for the existence of a sexually dimorphic nucleus in the preoptic area of the rat. J. Comp. Neural. 193, 529-539.
36. Gräf, K-J., Brotherton, J., and Neumann, F. (1974). Clinical uses of antiandrogens. Handbook Exp. Pharmacol. 35(2), 485-542.
37. Greenblatt, R. B., Barfield, W. E., Jungck, E. C., and Ray, A. W. (1961). Induction of ovulation with MRL-41. Preliminary report. JAMA 178, 101-104.
38. Gustafson, M. L., and Donahoe, P. K. (1994). Male sex determination: Current concepts of male sexual differentiation. Annu. Rev. Med. 45, 505-524.
39. Gustafson, M. L., Lee, M. M., Scully, R. E., Moncure, A. C., Hirakawa, T., Goodman, A., Muntz, H. G., Donahoe, P. K., MacLaughlin, D. T., and Fuller, A. F. (1992). Müllerian inhibiting substance as a marker for ovarian sex-cord tumor. New Engl. J. Med. 326, 466-471.
40. Hardy, M. P., Kirby, J. D., Hess, R. A., and Cooke, P. S. (1993). Leydig cells increase their numbers but decline in steroidogenic function in the adult rat after neonatal hypothyroidism. Endocrinology 132, 2417-2420.
41. Harper, M. J. K., and Walpole, A. L. (1967). Mode of action of ICI 46,474 in preventing implantation in rats. J. Endocrinol. 37, 83-92.
42. Harrington, J. M., Stein, G. F., Rivera, R. O., and de Morales, A. V. (1978). Occupational exposure to synthetic estrogens-A survey of plant employees. Arch. Environ. Health 33, 12-15.
43. Herbst, A. L., Cole, P., Colton, T., Robboy, S. J., and Scully, R. E. (1977). Age-incidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix. Am. J. Obstet. Gynecol. 128, 43-48.
44. Herbst, A. L., Ulfelder, H., and Poskanzer, D. C. (1971). Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. New Engl. J. Med. 284, 878-881.
45. Hess, R. A., Cooke, P. S., Bunick, D., and Kirby, J. D. (1993). Adult testicular enlargement induced by neonatal hypothyroidism is accompanied by increased Sertoli and germ cell numbers. Endocrinology 132, 2607-2613.
46. Huppert, L. C. (1979). Induction of ovulation with clomiphene citrate. Fertil. Steril. 31, 1-8.
47. Imperato-McGinley, J., Peterson, R. E., and Gautier, T. (1981). Male pseudo-hermaphroditism secondary to 5α-reductase deficiency: A review. Fetal Endocrinol., 359-382.
48. Imperato-McGinley, J., Sanchez, R. S., Spencer, J. R., Yee, B., and Vaughan, E. D. (1992). Comparison of the effects of the 5 α-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: Dose-response studies. Endocrinology 131, 1149-1156.
49. Jordan, V. C., and Murphy, C. S. (1990). Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 11, 578-610.
50. Jost, A. (1947). Recherches sur la différenciation sexuelle de l'embryon de lapin. Arch. Anat. Microscop. Morphol. Exp. 36, 151-200, 242-270, 271-315.
51. Katkam, R. R., Gopalkrishnan, K., Chwalisz, K., Schillinger, E., and Puri, C. P. (1995). Onapristone (ZK 98,299): A potential antiprogestin for endometrial contraception. Am. J. Obstet. Gynecol. 173, 779-787.
52. Katzenellenbogen, B. S., Montano, M. M., Kraus, W. L., Aronica, S. M., Fujimoto, N., and LeGoff, P. (1995). Estrogen-receptor and antiestrogen-receptor complexes: Cell- and promoter-specific effects and interactions with second messenger signaling pathways. In Organ-Selective Actions of Steroid Hormones (D. T. Baird, G. Schütz, and R. Krattenmacher, Eds.), Ernst Schering Research Foundation Workshop 16, pp. 29-50. Springer-Verlag, Berlin, Heidelberg.
53. Kelce, R. W., Stone, R. C., Laws, C. S., Gray, E. L., Kemppainen, A. J., and Wilson, M. E. (1995). Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature 373, 581-585.
54. Kenakin, T. P., Bond, R. A., and Bonner, T. I. (1992). II. Definition of pharmacological receptors. Pharmacol. Rev. 44, 351-362.
55. Kettel, L. M., Murphy, A. A., Mortola, J. F., Liu, J. H., Ulmann, A., and Yen, S. S. C. (1991). Endocrine response to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil. Steril. 56, 402-407.
56. Klein-Hitpass, L., Cato, A. C. B., Henderson, D., and Ryffel, G. U. (1991). Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 19, 1227-1234.
57. Klopper, A. (1985). Infertility. Br. Med. J. 290, 140-142.
58. Knowlton, K., Kenyon, A. T., Sandiford, I, Lotwin, G., and Fricker, R. (1942). Comparative study of metabolic effects of estradiol benzoate and testosterone proprionate in man. J. Clin. Endocrinol. Metab. 2, 671-684.
59. Koch, E., Thiel, R., Chahoud, I., and Neubert, D. (1995). Four generation reproductive toxicity study with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. I. Toxicokinetic variations in dams and offspring. Arch. Toxicol. 69, 271-279.
60. Ledger, W. L., Sweeting, V. M., Hillier, H., and Baird, D. T. (1992). Inhibition of ovulation by low-dose mifepristone (RU 486). Hum. Reprod. 7, 945-950.
61. Lipshultz, L. I., Ross, C. E., Ehorton, D., Milby, T., Smith, R., and Joyner, R. E. (1980). Dibromomonochloropropane and its effect on testicular function in man. J. Urol. 124, 464-468.
62. Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., and DeMets, D. L. (1992). Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl. J. Med. 326, 852-856.
63. Mably, T. A., Moore, R. W., Bjerke, D. L., and Peterson, R. E. (1991). The male reproductive system is highly sensitive to in utero and lactational TCDD exposure. Banbury Rep. 35, 69-78.
64. Mably, T. A., Moore, R. W., and Peterson, R. E. (1992a). In utero and lactational exposure of male rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 1. Effects on androgenic status. Toxicol. Appl. Pharmacol. 114, 97-107.
65. Mably, T. A., Moore, R. W., Goy, R. W., and Peterson, R. E. (1992b). In utero and lactational exposure of male rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 2. Effects on sexual behavior and the regulation of luteinizing hormone secretion in adulthood. Toxicol. Appl. Pharmacol. 114, 108-117.
66. Mably, T. A., Bjerke, D. L., Moore, R. W., Gendron-Fitzpatrick, A., and Peterson, R. E. (1992c). In utero and lactational exposure of male rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 3. Effects on spermatogenesis and reproductive capability. Toxicol. Appl. Pharmacol. 114, 118-126.
67. Mack, T. M., and Ross, R. K. (1989). Risks and benefits of long-term treatment with estrogens. Schweiz Med. Wochenschr. 119, 1811-1820.
68. Mallidis, C., Howard, E. J., and Baker, H. W. G. (1991). Variation of semen quality in normal men. Int. J. Androl. 14, 99-107.
69. McDonnell, D. P., Lieberman, B. A., and Norris, J. (1995). Development of tissue-selective estrogen receptor modulators. In OrganSelective Actions of Steroid Hormones (D. T. Baird, G. Schütz, and R. Krattenmacher, Eds.), Ernst Schering Research Foundation Workshop 16, pp. 1-28. Springer-Verlag, Berlin, Heidelberg,.
70. Meyer, M. E., Pernon, A., Jingwei, J., Bocquel, M. T., Chambon, P., and Gronemeyer, H. (1990). Agonistic and antagonistic activities of RU 486 on the functions of the human progesterone receptor. EMBO J. 12, 3923-3932.
71. Naghma-E-Rehan, Sobrero, A. J., and Fertig, J. W. (1975). The semen of fertile men: Statistical analysis of 1300 men. Fertil. Steril. 26, 492-502.
72. Negro-Vilar, A. (1993). Stress and other environmental factors affecting fertility in men and women: Overview. Environ. Health Perspect. 101(Suppl.), 59-64.
73. Nestor, J. J., Tahilramani, R., Ho, T. L., Goodpasture, J. C., Vickery, B. H., and Ferrandon, P. (1992). Potent gonadotropin-releasing hormone antagonists with low histamine-releasing activity. J. Med. Chem. 35, 3942-3948.
74. Neubert, D., and Chahoud, I. (1996). Possible consequences of preor early postnatal exposure to substances with estrogenic or androgenic properties. In Endocrinically Active Chemicals in the Environment (A. Gies and A. Wenzel, Eds.), pp. 24-52. Bundesumweltamt, Berlin.
75. Neumann, F., and Steinbeck, H. (1974). Antiandrogens. Handbook Exp. Pharmacol. 35(2), 235-484.
76. Oertel, G. (1973). Chemie der Androgene. Handbook Exp. Pharmacol. 35(1), 98-159.
77. Orth, J. M. (1982). Proliferation of Sertoli cells in fetal and postnatal rats: A quantitative autoradiographic study. Anat. Rec. 203, 485-492.
78. Orth, J. M., Gunsalus, G., and Lamperti, A. A. (1988). Evidence from Sertoli cell-depleted rats indicates that spermatid number in adults depends on number of Sertoli cells produced during perinatal development. Endocrinology 122, 787-794.
79. Pavlou, S. N., Brewer, K., Farley, M. G., Lindner, J., Bastias, M.-C., Rogers, B. J., Swift, L. L., Rivier, J. E., Vale, W. W., Conn, P. M., and Herbert, C. M. (1991). Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J. Clin. Endocrinol. Metab. 73, 1360-1369.
80. Peyron, R., Aubény, E., Targosz, V., Silvestre, L., Renault, M., Elkik, F., Leclerc, P., Ulmann, A., and Baulieu, E.-E. (1993). Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. New Engl. J. Med. 328, 1509-1513.
81. Poller, L., Thomson, J. M., Otridge, B. W., Yee, K F., and Logan, S. H. M. (1979). Effects of manufacturing oral contraceptives on blood clotting. Br. Med. J. 1, 1761-1762.
82. Ravdin, P. M., Fritz, N. F., Tormey, D. C., and Jordan, V. C. (1988). Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res. 48, 1026-1029.
83. Roman, B. L., Sommer, R. J., Shinoyima, K., and Peterson, R. E. (1995). In utero and lactational exposure of the male rat to 2,3,7,8-tetrachlorodibenzo-p-dioxin: Impaired prostate growth and development without inhibited androgen production. Toxicol. Appl. Pharmacol. 134, 241-250.
84. Rune, G. M., de Souza, P., Krowke, R., Merker, H.-J., and Neubert, D. (1991a). Morphological and histochemical effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on marmoset (Callithrix jacchus) testes. Arch. Androl. 26, 139-150.
85. Rune, G. M., de Souza, P., Krowke, R., Merker, H.-J., and Neubert, D. (1991b). Morphological and histochemical pattern of response after administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rat testes. Histol. Histopathol. 6, 459-467.
86. Safe, S., Harris, M., Biegel, L., and Zacharewski, T. (1991). Mechanism of action of TCDD as an antiandrogen in transformed human breast cancer and rodent cell lines. Banbury Rep. 35, 367-375.
87. Schwartz, D., Laplanche, A., Jouannet, P., and David, G. (1979). Within-subject variability of human semen in regard to sperm count, volume, total number of spermatozoa and length of abstinence. J. Reprod. Fertil. 57, 391-395.
88. Sharlip, I. D. (1985). Clinical andrology. In General Urology (D. R. Smith, Ed.), 11th ed., pp. 608-630. Lange Med. Publ., Los Altos, CA.
89. Stahlmann, R., Klug, S., Lewandowski, C., Bochert, G., Chahoud, I., Rahm, U., Merker, H.-J., and Neubert, D. (1988). Prenatal toxicity of acyclovir in rats. Arch. Toxicol. 61, 468-479.
90. Steinberger, E. (1992). Disorders of the male reproductive system. In Principles and Practice of Environmental Medicine (A. Bezman Tarcher, Ed.), pp. 437-457. Plenum Med. Book Co., NY.
91. Stieve, H. (1952). Der Einfluβ des Nervensystems auf Bau und Tätigkeit der Geschlechtsorgane des Menschen, pp. 1-191. Georg Thieme Verlag, Stuttgart.
92. Trachtenberg, J., and Pont, A. (1984). Ketoconazole for advanced prostate cancer. Lancet ii, 433-435.
93. Tsai, M.-J., and O'Malley, B. W. (1994). Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451-486.
94. Turner, R. T., Riggs, B. L., and Spelsberg, T. C. (1994). Skeletal effects of estrogens. Endocr. Rev. 15, 275-300.
95. Umbreit, T. H., and Gallo, M. A. (1988). Physiological implications of estrogen receptor modulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Lett. 42, 5-14.
96. van Haaster, L. H., De Jong, F. H., Docter, R., and de Rooij, D. G. (1993). High neonatal triiodothyronine levels reduce the period of Sertoli cell proliferation and accelerate tubular lumen formation in the rat testis and increase serum inhibin levels. Endocrinology 133, 755-760.
97. Vanden Bossche, H., Koymans, L., and Moereels, H. (1995). P450 inhibitors of use in medical treatment: Focus on mechanism of action. Pharmacol. Ther. 67, 79-100.
98. Vanden Bossche, H., Moereels, H., and Koymans, L. M. H. (1994). Aromatase inhibitors-Mechanism for non-steroidal inhibitors. Breast Cancer Res. Treat. 30, 43-55.
99. Vermeulen, A., Giagulli, V. A., De Schepper, P., Buntinx, A., and Stoner, E. (1989). Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans. Prostate 14, 45-53.
100. Vidal-Puig, A.J., Munos-Torres, M., Jódar-Gimeno, E., García-Calvente, C., Lardelli, P., Ruiz-Requena, M. E., and Escobar-Jiménez, F. (1994). Ketoconazole therapy: Hormonal and clinical effects in non-tumoral hyperandrogenism. Eur. J. Endocrinol. 130, 333-338.
101. Voss, H. E. (1973). Die Ausschaltung der Hodenfunktion. Handbook Exp. Pharmacol. 35(1), 79-97.
102. Whorton, D., Milby, T. H., Krauss, R. M., and Stubbs, H. A. (1979). Testicular function in DBCP exposed pesticide workers. J. Occup. Med. 21, 161-166.
103. Whorton, M. D., and Milby, T. H. (1980). Recovery of testicular function among DBCP workers. J. Occup. Med. 22, 177-179.
104. Yager, J. D., and Yager, R. (1980). Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res. 40, 3680-3685.